Resistance to activated protein C: Role in venous and arterial thrombosis

Biomedicine and Pharmacotherapy

Volumn 50, Issue 6-7, 1996, Pages 254-260

  Emmerich, J ^a   Alhenc Gelas, M ^b   Aiach, M ^b   Fiessinger, J N ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Activated protein C resistance; Factor V; Genetics; Thrombophilia; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5; GLUTAMINE;

ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; HEART INFARCTION; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MUTATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0029758686     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/0753-3322(96)84822-0     Document Type: Article

References (64)

1. 1 Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Bloom AL, Forbes CD, Thomas DP Tuddenham EGD (eds). Haemostasis and Thrombosis. New York: Churchil Livingstone, 1994:1327
2. 2 Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrhag 1965;13:516-30
3. 3 Pabinger I, Brücker S, Kyrle PA et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibrinol 1992;3:547-53
4. 4 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8
5. 5 Esmon C. The protein C anticoagulant pathway. Arterioscl Thrombos 1992;12:135-45
6. 6 Seligsohn U, Berger A, Abend M et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984;310:559-62
7. 7 Mahasandana C, Suvatte V, Marlar RA, Johnson MJ, Jacobson LJ, Hathaway WE. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990;335:61-2
8. 8 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-400
9. 9 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994;83:3120-5
10. 10 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994;269:18735-8
11. 11 Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. Thromb Haemost 1995;73:727-38
12. 12 Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7
13. 13 Majerus PW. Bad blood by mutation. Nature 1994;369: 14-5
14. 14 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH. Activated protein C resistance caused by Arg 506 Gln mutation in factor Va. Lancet 1994;343:1362-3
15. 15 Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln 506-factor V. Blood 1995;85: 3405-11
16. 16 Legnani C, Palareti G, Biagi R, Coccheri S. Activated protein C resistance in deep-vein thrombosis. Lancet 1994; 343:541-2
17. 17 Girolami A, Legnani C, and Rosendaal FR. Evaluation of activated protein C resistance in stored plasma. Lancet 1994;343:1288-90
18. 18 Alhenc-Gelas M, Gandrille S, Aubry ML, Emmerich J, Fiessinger JN, Aiach M. Unexplained thrombosis and factor Leiden mutation. Lancet 1994;344:555
19. 19 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-93
20. 20 Koster T, Rosendaal FR, De Ronde H, Briët E, Vanden broucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6
21. 21 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22
22. 22 Legnani C, Plareti G, Biagi P, Coccheri S. Activated protein C resistance in deep vein thrombosis. Lancet 1994; 343:541-2
23. 23 Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994;83:2008-9
24. 24 Trossaërt M, Conard J, Horellou M.H, Samaha M, Elalamy I, Samama MM. Résistance à la protéine C activée dans les accidents thromo-emboliques veineux: fréquence et manifestations cliniques. Presse Med 1995;24:209-12
25. 25 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4
26. 26 Dahlbäck B. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 1995;125:566-71
27. 27 Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994;94:923-7
28. 28 Dahlbäck B. Resistance to activated protein C, the Ag 506 to Gln mutation in the factor V gene, and venous thrombosis. Thromb Haemost 1995;73:739-42
29. 29 Greengard J, Eichinger S, Griffin JH, Bauer K. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg → Gln mutation in the gene for factor V. N Engl J Med 1994;331:1559-62
30. 30 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-8
31. 31 Simioni P, Scudeller A, Girolami A. Factor V Leiden and thrombophilia. N Engl J Med 1995;332:1382
32. 32 Alhenc-Gelas M, Emmerich J, Gandrille S et al. Protein C perfusion in a patient with inherited protein C deficiency caused by two missense mutations: Arg 178 to Gln and Arg-1 to His. Blood Coag Fibrinol 1994;6:35-41
33. 33 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4
34. 34 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7
35. 35 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptive: results of international multicentre case-control study. Lancet 1995;346:1575-82
36. 36 Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2
37. 37 Levoir D, Emmerich J, Alhenc-Gelas M et al. Portal vein thrombosis and factor V Arg 506 to Gln mutation. Thromb Haemost 1995;73:550-51
38. 38 Denninger MH, Beldjord K, Durand F, Denié C, Valla D, Guillin MC. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995;345:525-6
39. 39 Mahmoud AEA, Wilde JT, Elias E. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995;345:526
40. 40 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72:477-80
41. 41 Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-5
42. 42 Gandrille S, Greengard JS, Alhenc-Gelas M et al. Incidence of activated protein resistance cused by the Arg 506 Gln mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995;86:219-24
43. 43 Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85:3518-23
44. 44 Gandrille S, Borgel D, Aiach M. Incidence of activated protein C resistance due to Arg 506 Gln mutation in factor V in 116 unrelated propositus from families with protein S deficiency. Thromb Haemost 1995;73:1372
45. 45 Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993;70:1067-71
46. 46 Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344:952-3
47. 47 Lindblad B, Svensson PJ, Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 1994;343:917
48. 48 Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994;5:51-7
49. 49 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7
50. 50 Emmerich J, Poirier O, Evans A et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995;35:321
51. 51 März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526-7
52. 52 Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995;1:185
53. 53 Kontula K, Ylikorkala A, Miettinen H et al. Arg 506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558-60
54. 54 Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994;344:1709-10
55. 55 Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 G → A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 1995;73:521-4
56. 56 Eritsland J, Gjonnes G, Sandset PM et al. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995;79:223-6
57. 57 Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 1995;345:795
58. 58 Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994;72:647
59. 59 Hopmeier P, Krugluger W. Factor V Leiden and thrombophilia. N Engl J Med 1994;332,1381-2
60. 60 Zöller B, He X, Dahlbäck B. Homozygous APC resistance combined with inherited protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995;73:743-5
61. 61 Villa P, Aznar J, Jorquera J, Mira Y, Vaya A, Fernandez MA. Inherited homozygous resistance to activated protein C. Thromb Haemost 1995;74:794-5
62. 62 Samama MM, Trossaërt M, Horellou MH, Elalamy I, Conard J, Deschamps A. Risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995;86: 4700-1
63. 63 Emmerich J, Aiach M. Myocardial infarction and Arg 506 to Gln factor V mutation. N Engl J Med 1995;333:880-1
64. 64 Zöller B. Familial thrombophilia. Resistance to activated protein C and protein S deficiency. Thesis. Department of Clinical Chemistry, University of Lund. University Hospital Malmö, Sweden, 1996